Drug Discovery at UNC will also focus on utilizing the world-class capabilities across the University and partnering with external entities to further help deliver potential new therapeutics across the translational research gap. UNC has already seen success in completing impactful translational research and this effort aims to build on that success.
Projects will benefit from close collaborations with the Center for Integrated Chemical Biology and Drug Discovery (CICBDD), the Lineberger Comprehensive Cancer Center and other UNC resources, as well as additional future partnerships with external groups around antibodies and biologics, mRNA technologies and pre-clinical DMPK/Tox.
We will communicate additional DDI resources as they become available over time.
Novel Target Identification
- UNC CRISPR Genetic and Epigenetic Screening Center (Opening Q3 ’21)
- Small Molecule: DNA-Encoded Libraries (DEL)
- Collaboration with HitGen
- Antibody Screening
Translational Research/ Asset Development
- On-Campus Capabilities
- Small Molecule
- Cell/Gene Therapies
- CRO/External Partnerships
- Small Molecules
- mRNA Technologies
- Available now or by end of 2021
- Available in 2022